How to buy Silverback Therapeutics (SBTX) stock

Silverback Therapeutics, Inc is a biotechnology business based in the US. Silverback Therapeutics shares (SBTX) are listed on the NASDAQ and all prices are listed in US Dollars. Silverback Therapeutics employs 67 staff and has a market cap (total outstanding shares value) of 0.00.

Silverback Therapeutics stock price (NASDAQ: SBTX)

Use our graph to track the performance of SBTX stocks over time.

Silverback Therapeutics shares at a glance

• Key figures

Information last updated 2021-07-23.

Latest market close	$27.53
52-week range	$21.00 - $63.41
50-day moving average	$30.99
200-day moving average	$38.65
Wall St. target price	$50.20
PE ratio	N/A
Dividend yield	N/A (0%)
Earnings per share (TTM)	N/A

Buy Silverback Therapeutics shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

*Signup bonus information updated weekly.

Is it a good time to buy Silverback Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of Silverback Therapeutics, Inc by TradingView

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Silverback Therapeutics price performance over time

Historical closes compared with the close of $27.53 from 2021-05-28

1 week (2021-07-17)	N/A
1 month (2021-06-28)	-14.05%
3 months (2021-04-28)	-20.71%
6 months (2021-01-24)	N/A

1 year (2020-07-24)	N/A
2 years (2019-07-24)	N/A
3 years (2018-07-24)	N/A
5 years (2016-07-24)	N/A

Silverback Therapeutics financials

Gross profit TTM	$0
Return on assets TTM	-10.03%
Return on equity TTM	-17.47%
Profit margin	0%
Book value	$10.58
Market capitalisation	$1.2 billion

TTM: trailing 12 months

Shorting Silverback Therapeutics shares

There are currently 3.2 million Silverback Therapeutics shares held short by investors – that's known as Silverback Therapeutics's "short interest". This figure is 3.7% down from 3.3 million last month.

There are a few different ways that this level of interest in shorting Silverback Therapeutics shares can be evaluated.

Silverback Therapeutics's "short interest ratio" (SIR)

Silverback Therapeutics's "short interest ratio" (SIR) is the quantity of Silverback Therapeutics shares currently shorted divided by the average quantity of Silverback Therapeutics shares traded daily (recently around 133017.15951687). Silverback Therapeutics's SIR currently stands at 24.01. In other words for every 100,000 Silverback Therapeutics shares traded daily on the market, roughly 24010 shares are currently held short.

To gain some more context, you can compare Silverback Therapeutics's short interest ratio against those of similar companies.

• FibroGen (FGEN.US): 8.13
• Gilead Sciences (GILD.US): 3.52
• GlaxoSmithKline (GSK.US): 2.85
• HCA Healthcare (HCA.US): 2.69

However Silverback Therapeutics's short interest can also be evaluated against the total number of Silverback Therapeutics shares, or, against the total number of tradable Silverback Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Silverback Therapeutics's short interest could be expressed as 0.09% of the outstanding shares (for every 100,000 Silverback Therapeutics shares in existence, roughly 90 shares are currently held short) or 0.1802% of the tradable shares (for every 100,000 tradable Silverback Therapeutics shares, roughly 180 shares are currently held short).

A SIR above 20% would generally be considered very high, pointing to a pessimistic outlook for the share price, with a discouraging number of investors currently willing to bet against Silverback Therapeutics.

Find out more about how you can short Silverback Therapeutics stock.

Silverback Therapeutics share dividends

We're not expecting Silverback Therapeutics to pay a dividend over the next 12 months.

You may also wish to consider:

• Gilead Sciences (GILD.US) (4.02% forward annual dividend yield)
• GlaxoSmithKline (GSK.US) (2.03% forward annual dividend yield)
• HCA Healthcare (HCA.US) (0.39% forward annual dividend yield)

Silverback Therapeutics overview

Silverback Therapeutics, Inc. , a clinical-stage biopharmaceutical company, develops tissue targeted therapeutics for the treatment of cancer, chronic viral infections, and other serious diseases. Its lead product candidate is SBT6050, which is in a Phase I/Ib clinical trial, a TLR8 agonist linker-payload conjugated to a HER2-directed monoclonal antibody that targets tumors, such as breast, gastric, and non-small cell lung cancers. The company also focuses on developing SBT6290, a product candidate that is in preclinical stage, which is a TLR8 linker-payload conjugated to a monoclonal antibody that targets Nectin4, which is expressed in bladder, triple negative breast, head and neck, and non-small cell lung cancers. In addition, it engages in developing SBT8230, a TLR8 linker-payload conjugated to an ASGR1 monoclonal antibody that is under development for the treatment of chronic hepatitis B virus infection; and agents that localize therapies to modulate pathways in additional oncology and fibrosis indications using TLR8 and other linker-payloads. Silverback Therapeutics, Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.

Frequently asked questions

What percentage of Silverback Therapeutics is owned by insiders or institutions?
Currently 8.367% of Silverback Therapeutics shares are held by insiders and 86.249% by institutions. How many people work for Silverback Therapeutics?
Latest data suggests 67 work at Silverback Therapeutics. When does the fiscal year end for Silverback Therapeutics?
Silverback Therapeutics's fiscal year ends in December. Where is Silverback Therapeutics based?
Silverback Therapeutics's address is: 500 Fairview Avenue North, Seattle, WA, United States, 98109